ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, with disease control generally lasting approximately one year [32], this performance falls far short of the efficacy of BCR-ABL inhibitors for chronic myeloid leukemia, which feature five-year disease-control rates exceeding 90% [1,33].